{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:51:06Z","timestamp":1783536666205,"version":"3.55.0"},"reference-count":497,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2024.103179","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:34:27Z","timestamp":1711636467000},"page":"103179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Developmental drugs for sarcoidosis"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-1345","authenticated-orcid":false,"given":"Ogugua Ndili","family":"Obi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley Ann","family":"Saketkoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib1","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med. 04"},{"issue":"10 Pt 1","key":"10.1016\/j.jaut.2024.103179_bib2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med. Nov"},{"key":"10.1016\/j.jaut.2024.103179_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib4","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Oct"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib5","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103179_bib7","first-page":"26","article-title":"Systemic treatment in sarcoidosis: experience over two decades","author":"Fernandez-Ramon","year":"2022","journal-title":"Eur J Intern Med. Nov"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest. Jan"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib9","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J. May"},{"key":"10.1016\/j.jaut.2024.103179_bib10","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med. 08"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib11","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J. Dec"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","volume":"11","author":"James","year":"2018","journal-title":"Expert Rev Clin Pharmacol. Jul"},{"key":"10.1016\/j.jaut.2024.103179_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2024.103179_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103179_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000000985","article-title":"Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care","author":"Francesqui","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib16","article-title":"Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis","volume":"38","author":"Harman","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib17","article-title":"First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative","volume":"6","author":"Kampstra","year":"2019","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000602","article-title":"Patient perspectives in sarcoidosis","volume":"25","author":"van Helmondt","year":"2019","journal-title":"Curr Opin Pulm Med. 09"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur Respir J. Jul"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/pathophysiology28040035","article-title":"Small fiber neuropathy in sarcoidosis","volume":"28","author":"Gavrilova","year":"2021","journal-title":"Pathophysiology"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000893","article-title":"Novel insights in fibrotic pulmonary sarcoidosis","volume":"28","author":"Comes","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"166","key":"10.1016\/j.jaut.2024.103179_bib22","first-page":"31","article-title":"Immune mechanisms in fibrotic pulmonary sarcoidosis","author":"Weeratunga","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jaut.2024.103179_bib23","first-page":"1","article-title":"Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update","volume":"31","author":"Obi","year":"2021","journal-title":"Expert Rev Clin Pharmacol. Jan"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib24","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: wells Law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2024.103179_bib25","volume":"vol. 8","author":"Judson","year":"2019"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib27","first-page":"155","article-title":"The burden of sarcoidosis symptoms from a patient perspective. Lung","volume":"197","author":"Voortman","year":"2019","journal-title":"Apr"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"Michielsen","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCP.0000000000000597","article-title":"Nonorgan manifestations of sarcoidosis","volume":"25","author":"Tavee","year":"2019","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaut.2024.103179_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/IMI.S12783","article-title":"Shared decision making: a fundamental tenet in a conceptual framework of integrative healthcare delivery","volume":"8","author":"Brooks","year":"2013","journal-title":"Integr. Med. Insights"},{"key":"10.1016\/j.jaut.2024.103179_bib32","first-page":"109","article-title":"Fostering shared decision making with health informatics interventions based on the boosting framework","volume":"263","author":"de Vries","year":"2019","journal-title":"Stud Health Technol Inform"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib34","first-page":"10","article-title":"Benefit of wearing an activity tracker in sarcoidosis","author":"Drent","year":"2020","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: review and experience-based recommendations","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expert Rev Respir Med. 10"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis","volume":"193","author":"Strookappe","year":"2015","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib37","first-page":"43","article-title":"Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study","volume":"32","author":"Strookappe","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib38","article-title":"A comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc","volume":"35","author":"Saketkoo","year":"2021","journal-title":"Best Pract Res Clin Rheumatol. Sep"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(22)00387-3","article-title":"Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial","volume":"11","author":"Kahlmann","year":"2023","journal-title":"Lancet Respir Med. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med. Nov"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis. Jul"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib42","first-page":"7","article-title":"Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids","author":"Entrop","year":"2021","journal-title":"ERJ Open Res. Apr"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med. Apr"},{"issue":"155","key":"10.1016\/j.jaut.2024.103179_bib44","first-page":"29","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"31","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev. Mar"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax. Mar"},{"issue":"155","key":"10.1016\/j.jaut.2024.103179_bib46","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev. Mar"},{"issue":"18","key":"10.1016\/j.jaut.2024.103179_bib47","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1080\/14656566.2016.1258061","article-title":"Sarcoidosis: an update on current pharmacotherapy options and future directions","volume":"17","author":"Brito-Zeron","year":"2016","journal-title":"Expert Opin Pharmacother. Dec"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study","volume":"104","author":"Schutt","year":"2010","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr Opin Pulm Med. Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/14799731211031935","article-title":"Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population","volume":"18","author":"Kahlmann","year":"2021","journal-title":"Chron. Respir. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib51","article-title":"Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jaut.2024.103179_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/s00408-020-00323-8","article-title":"Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis","author":"Drent","year":"2020","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J. Jun"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med. Oct"},{"key":"10.1016\/j.jaut.2024.103179_bib55","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0873-2159(15)30403-7","article-title":"Tumor necrosis factor inhibition in treating sarcoidosis: the American experience","volume":"13","author":"Baughman","year":"2007","journal-title":"Revista Portuguesa de Pneumonologia"},{"key":"10.1016\/j.jaut.2024.103179_bib56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000906","article-title":"Hit-hard and early versus step-up treatment in severe sarcoidosis","volume":"28","author":"Vorselaars","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J. Jul"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib59","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur Respir J. Jun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum. Aug"},{"key":"10.1016\/j.jaut.2024.103179_bib61","first-page":"834","article-title":"Use of third-line therapies in advanced sarcoidosis","volume":"38","author":"Lower","year":"2020","journal-title":"Clin Exp Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib62","article-title":"Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: an introduction by the global fellowship on rehabilitation and exercise in systemic sclerosis (G-FoRSS)","volume":"35","author":"Pettersson","year":"2021","journal-title":"Best Pract Res Clin Rheumatol. Sep"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib63","article-title":"Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis","volume":"4","author":"Saketkoo","year":"2018","journal-title":"ERJ Open Res. Apr"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib64","article-title":"Comprehensive care for patients with sarcoidosis","volume":"9","author":"Moor","year":"2020","journal-title":"J Clin Med. Feb"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib65","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semdp.2018.09.001","article-title":"Reprint of: the pathology of pulmonary sarcoidosis: update","volume":"35","author":"Ma","year":"2018","journal-title":"Semin Diagn Pathol. Sep"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib66","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American thoracic society\/European respiratory society\/world association of sarcoidosis and other granulomatous disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Sep"},{"issue":"Supplement_6","key":"10.1016\/j.jaut.2024.103179_bib67","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"Moller","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaut.2024.103179_bib68","article-title":"Current perspectives on the immunopathogenesis of sarcoidosis","volume":"173","author":"Lee","year":"2020","journal-title":"Respir Med. Nov"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib69","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/all.13788","article-title":"Innate immunity in allergy","volume":"74","author":"Maeda","year":"2019","journal-title":"Allergy. Sep"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib70","first-page":"218","article-title":"CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope","author":"Greaves","year":"2021","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib71","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.4049\/jimmunol.181.12.8784","article-title":"T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol. Dec"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib72","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1128\/IAI.00142-09","article-title":"Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis","volume":"77","author":"Oswald-Richter","year":"2009","journal-title":"Infect Immun. Sep"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10875-009-9311-y","article-title":"Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101","volume":"30","author":"Oswald-Richter","year":"2010","journal-title":"J Clin Immunol. Jan"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib74","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10875-012-9700-5","article-title":"Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL","volume":"32","author":"Oswald-Richter","year":"2012","journal-title":"J Clin Immunol. Oct"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrrheum.2011.93","article-title":"Sarcoidosis--scientific progress and clinical challenges","volume":"7","author":"Chen","year":"2011","journal-title":"Nat Rev Rheumatol. Jul"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib76","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MCP.0b013e3283560809","article-title":"Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders","volume":"18","author":"Gupta","year":"2012","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"Baughman","year":"2006","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib78","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Jul"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib79","first-page":"65","article-title":"The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore)","volume":"78","author":"Johns","year":"1999","journal-title":"Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.537382","article-title":"Sarcoidosis epidemiology: race matters","volume":"11","author":"Hena","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib81","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","article-title":"From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis","volume":"22","author":"Bonham","year":"2016","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib82","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ajpath.2010.11.065","article-title":"M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis","volume":"178","author":"Prokop","year":"2011","journal-title":"Am J Pathol. Mar"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib83","first-page":"120","article-title":"Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"13","author":"Kunkel","year":"1996","journal-title":"Sep"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.it.2020.01.007","article-title":"Sarcoidosis and the mTOR, Rac1, and autophagy triad","volume":"41","author":"Pacheco","year":"2020","journal-title":"Trends Immunol. Apr"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ni.3655","article-title":"Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression","volume":"18","author":"Linke","year":"2017","journal-title":"Nat Immunol. Mar"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2353\/ajpath.2009.080580","article-title":"FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions","volume":"174","author":"Taflin","year":"2009","journal-title":"Am J Pathol. Feb"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib87","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med. Feb"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2011.03.015","article-title":"Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation","volume":"140","author":"Rappl","year":"2011","journal-title":"Clin Immunol. Jul"},{"key":"10.1016\/j.jaut.2024.103179_bib89","article-title":"Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis","author":"Crouser","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib90","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib91","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01450-2019","article-title":"Subpopulations of cells from bronchoalveolar lavage can predict prognosis in sarcoidosis","volume":"55","author":"Darlington","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib92","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2796.2012.02543.x","article-title":"T-cell phenotypes in bronchoalveolar lavage fluid, blood and lymph nodes in pulmonary sarcoidosis--indication for an airborne antigen as the triggering factor in sarcoidosis","volume":"272","author":"Darlington","year":"2012","journal-title":"J Intern Med. Nov"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib93","article-title":"Models contribution to the understanding of sarcoidosis pathogenesis: \"are there good models of sarcoidosis?\"","volume":"9","author":"Besnard","year":"2020","journal-title":"J Clin Med. Jul"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib94","first-page":"2095","article-title":"Biologic basis for interleukin-1 in disease. Blood","volume":"87","author":"Dinarello","year":"1996","journal-title":"Mar 15"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib95","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol. Oct"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev. Jan"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40136-018-0181-9","article-title":"Treatment of inflammatory diseases with IL-1 blockade","volume":"6","author":"Dinarello","year":"2018","journal-title":"Curr Otorhinolaryngol Rep"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib98","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol. Nov"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib99","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103179_bib100","article-title":"IL-1 family cytokines as drivers and inhibitors of trained immunity","volume":"150","author":"Teufel","year":"2022","journal-title":"Cytokine. Feb"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib101","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med. Jul"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib102","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.4049\/jimmunol.165.8.4718","article-title":"Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis","volume":"165","author":"Greene","year":"2000","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib103","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.it.2019.09.005","article-title":"Emerging activators and regulators of inflammasomes and pyroptosis","volume":"40","author":"Xue","year":"2019","journal-title":"Trends Immunol. Nov"},{"issue":"5 Suppl 27","key":"10.1016\/j.jaut.2024.103179_bib104","first-page":"S1","article-title":"The IL-1 family and inflammatory diseases","volume":"20","author":"Dinarello","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1 Pt 1","key":"10.1016\/j.jaut.2024.103179_bib105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0091-6749(99)70518-X","article-title":"IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family","volume":"103","author":"Dinarello","year":"1999","journal-title":"J Allergy Clin Immunol. Jan"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib106","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccm.2015.08.016","article-title":"Cellular players in the immunopathogenesis of sarcoidosis","volume":"36","author":"Zissel","year":"2015","journal-title":"Clin Chest Med. Dec"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib107","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.161.7.3400","article-title":"IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production","volume":"161","author":"Yoshimoto","year":"1998","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib108","article-title":"Interleukin-18 in health and disease","volume":"20","author":"Yasuda","year":"2019","journal-title":"Int J Mol Sci. Feb 2"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.rmed.2006.08.019","article-title":"The clinical significance of interleukin 18 assessment in sarcoidosis patients","volume":"101","author":"Kieszko","year":"2007","journal-title":"Respir Med. Apr"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib110","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs","volume":"166","author":"Shigehara","year":"2001","journal-title":"J Immunol. Jan"},{"issue":"6256","key":"10.1016\/j.jaut.2024.103179_bib111","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/343336a0","article-title":"Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor","volume":"343","author":"Hannum","year":"1990","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib112","first-page":"353","article-title":"Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine","volume":"4","author":"Granowitz","year":"1992","journal-title":"Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib113","unstructured":"FDA. U. Anakinra. US Food and Drug Administration (FDA) approved product information. Accessed July 19, 2023, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/103950-0_Kineret.cfm."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1744666X.2019.1707664","article-title":"Canakinumab for the treatment of adult-onset Still's disease","volume":"16","author":"Sfriso","year":"2020","journal-title":"Expert Rev Clin Immunol. Feb"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib115","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1517\/14712598.2010.530653","article-title":"Canakinumab for treatment of cryopyrin-associated periodic syndrome","volume":"10","author":"Feist","year":"2010","journal-title":"Expert Opin Biol Ther. Nov"},{"key":"10.1016\/j.jaut.2024.103179_bib116","unstructured":"Administration UFaD. Canakinumab. US Food and Drug Administration (FDA) approved product information. Revised September 2016. Accessed July 20, 2023, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/BLA125319_858687lbl.pdf."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm811","article-title":"Cytokine traps: multi-component, high-affinity blockers of cytokine action","volume":"9","author":"Economides","year":"2003","journal-title":"Nat Med. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib118","unstructured":"Rilonacept. US Food and Drug Administration (FDA) approved product information. Revised 03\/2021. Accessed July 19, 2023, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125249lbl.pdf."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib119","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1038\/s41598-019-45747-2","article-title":"Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: a Mendelian randomization study","volume":"9","author":"Mokry","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150018","article-title":"A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus","volume":"11","author":"McKie","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2024.103179_bib122","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib123","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)","volume":"19","author":"Kron","year":"2021","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007582","article-title":"Inflammasome Formation in granulomas in cardiac sarcoidosis","volume":"12","author":"Kron","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib125","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.011869","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: a pilot study","volume":"16","author":"Kron","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib127","article-title":"The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation","volume":"55","author":"Huppertz","year":"2020","journal-title":"Eur Respir J. Mar"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib128","first-page":"629","article-title":"Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads","volume":"130","author":"Kasahara","year":"1988","journal-title":"Am J Pathol. Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000029536","article-title":"Significance of the interleukin-1 receptor antagonist\/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis","volume":"67","author":"Mikuniya","year":"2000","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/00365513.2010.506555","article-title":"The association between interleukin-18 and pulmonary sarcoidosis: a meta-analysis","volume":"70","author":"Liu","year":"2010","journal-title":"Scand J Clin Lab Invest. Oct"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/00365513.2011.597871","article-title":"Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis?","volume":"71","author":"Liu","year":"2011","journal-title":"Scand J Clin Lab Invest. Nov"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib132","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jir.2006.26.400","article-title":"Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis","volume":"26","author":"Antoniou","year":"2006","journal-title":"J Interferon Cytokine Res. Jun"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib133","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1164\/ajrccm.162.5.9911113","article-title":"Increased levels of interleukin-18 in patients with pulmonary sarcoidosis","volume":"162","author":"Shigehara","year":"2000","journal-title":"Am J Respir Crit Care Med. Nov"},{"key":"10.1016\/j.jaut.2024.103179_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1465-9921-15-15","article-title":"Cardiac involvement in Caucasian patients with pulmonary sarcoidosis","volume":"15","author":"Darlington","year":"2014","journal-title":"Respir Res. Feb"},{"issue":"Suppl 6","key":"10.1016\/j.jaut.2024.103179_bib135","first-page":"507","article-title":"Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis","volume":"59","author":"Mroz","year":"2008","journal-title":"J Physiol Pharmacol. Dec"},{"key":"10.1016\/j.jaut.2024.103179_bib136","unstructured":"ClinicalTrialsgov. Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis. Accessed June 25, 2022, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04064242."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib137","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.106.1.156","article-title":"Significance of interleukin 6 in patients with sarcoidosis","volume":"106","author":"Sahashi","year":"1994","journal-title":"Chest. Jul"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib138","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin Immunol. Jan"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib139","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ibd.21384","article-title":"Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis","volume":"17","author":"Terabe","year":"2011","journal-title":"Inflamm Bowel Dis. Feb"},{"issue":"3 Pt 1","key":"10.1016\/j.jaut.2024.103179_bib140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/ajrccm.154.3.8810610","article-title":"Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis","volume":"154","author":"Zissel","year":"1996","journal-title":"Am J Respir Crit Care Med. Sep"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib141","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib142","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol. Sep 4"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib143","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1164\/ajrccm.152.1.7599865","article-title":"Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis","volume":"152","author":"Girgis","year":"1995","journal-title":"Am J Respir Crit Care Med. Jul"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib144","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200905-0696OC","article-title":"Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2","volume":"181","author":"Chen","year":"2010","journal-title":"Am J Respir Crit Care Med. Feb"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib145","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","article-title":"Targeting the interleukin-6\/Jak\/stat pathway in human malignancies","volume":"30","author":"Sansone","year":"2012","journal-title":"J Clin Oncol. Mar 20"},{"issue":"26","key":"10.1016\/j.jaut.2024.103179_bib146","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib147","first-page":"38","article-title":"Progressive pulmonary sarcoidosis--a fibroproliferative process potentially triggered by EGR-1 and IL-6. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"23","author":"Bihl","year":"2006","journal-title":"Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib148","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2249.1997.d01-905.x","article-title":"Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters","volume":"107","author":"Takizawa","year":"1997","journal-title":"Clin Exp Immunol. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib149","first-page":"3787","article-title":"TNF-\u03b1, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course","volume":"42","author":"Denisova","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2024.103179_bib150","first-page":"96","article-title":"[IL-1, TNF and IL-6 production by alveolar mononuclear cells in patients with sarcoidosis]","volume":"122","author":"Pejnovic","year":"1994","journal-title":"Srp. Arh. Celok. Lek."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib151","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/ene.13975","article-title":"The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study","volume":"26","author":"Chazal","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib152","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/17425255.2015.992779","article-title":"Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics\/pharmacodynamics and clinical efficacy","volume":"11","author":"Song","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol. Feb"},{"issue":"15","key":"10.1016\/j.jaut.2024.103179_bib153","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jaut.2024.103179_bib154","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of sarilumab and its potential in the treatment of rheumatoid arthritis","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"14","key":"10.1016\/j.jaut.2024.103179_bib155","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40265-020-01391-z","article-title":"Correction to: Satralizumab: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib156","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","article-title":"Siltuximab: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs. Jul"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib157","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib158","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40259-018-0320-3","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what's the difference?","volume":"32","author":"Avci","year":"2018","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib159","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-018-4006-5","article-title":"Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials","volume":"37","author":"Bae","year":"2018","journal-title":"Clin Rheumatol. Jun"},{"key":"10.1016\/j.jaut.2024.103179_bib160","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"Sharp","year":"2019","journal-title":"Respir. Med. X"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib161","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1111\/aos.13015","article-title":"Outcome of tocilizumab treatment in refractory ocular inflammatory diseases","volume":"94","author":"Silpa-Archa","year":"2016","journal-title":"Acta Ophthalmol."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib162","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000508237","article-title":"Tocilizumab in a case of refractory idiopathic orbital inflammation: 6-year follow-up outcomes","volume":"11","author":"Artaechevarria Artieda","year":"2020","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.jaut.2024.103179_bib163","article-title":"A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis","author":"Baker","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103179_bib164","unstructured":"ClinialTrialsGov. Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis. U.S. National Library of Medicine. Accessed June 27, 2022, https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04008069."},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib165","first-page":"e217","article-title":"Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab","volume":"45","author":"Shono","year":"2018","journal-title":"J Dermatol. Aug"},{"key":"10.1016\/j.jaut.2024.103179_bib166","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14878","article-title":"Lung and liver sarcoidosis-like reaction induced by tocilizumab","author":"Lambert","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103179_bib167","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19841796","article-title":"New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review","volume":"11","author":"Del Giorno","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib168","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3899\/jrheum.130278","article-title":"Sarcoidosis induced by tocilizumab: a paradoxical event?","volume":"40","author":"Nutz","year":"2013","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib169","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.177.1.642","article-title":"A regulatory effect of the balance between TNF-alpha and IL-6 in the granulomatous and inflammatory response to Rhodococcus aurantiacus infection in mice","volume":"177","author":"Yimin","year":"2006","journal-title":"J Immunol. Jul 1"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib170","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2567.2003.01762.x","article-title":"Up-regulation of granulomatous inflammation in interleukin-6 knockout mice infected with Rhodococcus aurantiacus","volume":"110","author":"Yimin","year":"2003","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib171","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern Med J. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib172","article-title":"Pulmonary sarcoidosis following etanercept treatment","volume":"2012","author":"Bhamra","year":"2012","journal-title":"Case Rep Rheumatol"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib173","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/RHU.0b013e3181efa190","article-title":"Tumor necrosis factor-alpha antagonist-induced sarcoidosis","volume":"16","author":"Clementine","year":"2010","journal-title":"J Clin Rheumatol. Sep"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib174","first-page":"378","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy?","volume":"11","author":"Decock","year":"2017","journal-title":"J Crohns Colitis. Mar 1"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cytogfr.2014.07.017","article-title":"IL-12-and IL-23 in health and disease","volume":"25","author":"Croxford","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib176","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1164\/ajrccm.160.4.9807120","article-title":"Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis","volume":"160","author":"Taha","year":"1999","journal-title":"Am J Respir Crit Care Med. Oct"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib177","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","article-title":"Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells","volume":"154","author":"Macatonia","year":"1995","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib178","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/107999003322277865","article-title":"Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis","volume":"23","author":"Barbarin","year":"2003","journal-title":"J Interferon Cytokine Res. Aug"},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib179","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis","volume":"156","author":"Moller","year":"1996","journal-title":"J Immunol. Jun 15"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib180","first-page":"151","article-title":"Enhanced mRNA expression of Th1 cytokines and IL-12 in active pulmonary sarcoidosis","volume":"17","author":"Shigehara","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Jun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib181","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1365-2249.2003.02105.x","article-title":"Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis","volume":"132","author":"Shigehara","year":"2003","journal-title":"Clin Exp Immunol. Apr"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib182","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2007.01.010","article-title":"IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease","volume":"119","author":"Chi","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib183","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"Ivanov, II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"issue":"6924","key":"10.1016\/j.jaut.2024.103179_bib184","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature. Feb"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4049\/jimmunol.1801603","article-title":"The tale of IL-12 and IL-23: a paradigm shift","volume":"202","author":"Khader","year":"2019","journal-title":"J Immunol. Feb 1"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib186","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: one cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur J Immunol. Sep"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib187","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2011.06.017","article-title":"Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway","volume":"66","author":"Judson","year":"2012","journal-title":"J Am Acad Dermatol. Jun"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib189","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol. Jul"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib190","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J. Nov"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib191","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/cei.12942","article-title":"Sarcoidosis extent relates to molecular variability","volume":"188","author":"Monast","year":"2017","journal-title":"Clin Exp Immunol. 06"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib192","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1183\/09031936.00156314","article-title":"Negative clinical trials in sarcoidosis: failed therapies or flawed study design?","volume":"44","author":"Moller","year":"2014","journal-title":"Eur Respir J. Nov"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib193","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1513\/AnnalsATS.202208-731ED","article-title":"Pulmonary sarcoidosis: beyond restriction and forced vital capacity","volume":"20","author":"Obi","year":"2023","journal-title":"Ann Am Thorac Soc. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features","author":"Kouranos","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.202204-328OC","article-title":"Heterogeneity of lung function phenotypes in sarcoidosis: role of race and sex differences","volume":"20","author":"Sharp","year":"2023","journal-title":"Ann Am Thorac Soc. Jan"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib196","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1183\/09031936.03.00083002","article-title":"Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis","volume":"21","author":"Fehrenbach","year":"2003","journal-title":"Eur Respir J. Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib197","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10875-008-9225-0","article-title":"Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis","volume":"29","author":"Wiken","year":"2009","journal-title":"J Clin Immunol. Jan"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib198","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib199","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/CVI.00401-07","article-title":"Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients","volume":"15","author":"Newton","year":"2008","journal-title":"Clin Vaccine Immunol. Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib200","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1189\/jlb.0307133","article-title":"Expression and role of CCR6\/CCL20 chemokine axis in pulmonary sarcoidosis","volume":"82","author":"Facco","year":"2007","journal-title":"J Leukoc Biol. Oct"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib201","first-page":"144","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder. Thorax","volume":"66","author":"Facco","year":"2011","journal-title":"Feb"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib202","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09629350120102325","article-title":"Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-alpha and INF-gamma","volume":"10","author":"Sasaki","year":"2001","journal-title":"Mediators Inflamm"},{"issue":"6 Pt 1","key":"10.1016\/j.jaut.2024.103179_bib203","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1507","article-title":"Increased number of alveolar macrophages expressing surface molecules of the CD11\/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells","volume":"147","author":"Schaberg","year":"1993","journal-title":"Am Rev Respir Dis. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib204","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2249.2008.03841.x","article-title":"Giant cell formation in sarcoidosis: cell fusion or proliferation with non-division?","volume":"155","author":"van Maarsseveen","year":"2009","journal-title":"Clin Exp Immunol. Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2249.2001.01655.x","article-title":"Heightened ability of monocytes from sarcoidosis patients to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells","volume":"126","author":"Mizuno","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib206","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.152.3.7663784","article-title":"Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis","volume":"152","author":"Zheng","year":"1995","journal-title":"Am J Respir Crit Care Med. Sep"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib207","first-page":"185","article-title":"Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis","volume":"19","author":"Ziegenhagen","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Oct"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib208","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cyto.b.20120","article-title":"Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis","volume":"70","author":"Tutor-Ureta","year":"2006","journal-title":"Cytometry B Clin Cytom. Nov"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib209","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. : official journal of WASOG"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","article-title":"The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial","volume":"108","author":"Judson","year":"2014","journal-title":"Respir Med. Jan"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib211","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. : official journal of WASOG. Jan"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib212","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Apr"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib213","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J Am Acad Dermatol. May"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib214","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","article-title":"Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials","volume":"27","author":"Goto","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest. Jul"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib216","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2024.103179_bib217","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib218","article-title":"P. Controversies in the treatment of cardiac sarcodosis","volume":"39","author":"Obi","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib219","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jaut.2024.103179_bib220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"Effectiveness and safety of infliximab in cardiac Sarcoidosis","volume":"330","author":"Bakker","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"20","key":"10.1016\/j.jaut.2024.103179_bib221","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology. Nov"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib222","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib223","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J Neurol. May"},{"key":"10.1016\/j.jaut.2024.103179_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.970168","article-title":"Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review","volume":"13","author":"Sambon","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum. Dec"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib226","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation","volume":"43","author":"Baughman","year":"2005","journal-title":"Int J Clin Pharmacol Ther. Jan"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib227","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","article-title":"[Infliximab treatment for chronic sarcoidosis--a case series]","volume":"27","author":"Jounieaux","year":"2010","journal-title":"Rev. Mal. Respir."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib228","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest. Feb"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib229","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamadermatol.2017.1162","article-title":"Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases","volume":"153","author":"Heidelberger","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib230","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000314225","article-title":"Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment","volume":"80","author":"Elfferich","year":"2010","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib231","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"Parambil","year":"2011","journal-title":"Respir Med. Jan"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib232","first-page":"73","article-title":"Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab","volume":"23","author":"Hoitsma","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib233","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.jaut.2024.103179_bib234","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir Med. 06"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib235","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","article-title":"Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET","volume":"6","author":"Milman","year":"2012","journal-title":"Clin Respir J. Oct"},{"issue":"18","key":"10.1016\/j.jaut.2024.103179_bib236","article-title":"Long-Term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assoc. 09"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib237","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol. May"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib238","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/imt.14.65","article-title":"Anti-TNF therapeutics for the treatment of sarcoidosis","volume":"6","author":"Crommelin","year":"2014","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib239","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib240","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib241","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","article-title":"Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept","volume":"21","author":"Shen","year":"2005","journal-title":"Aliment Pharmacol Ther. Feb 1"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib242","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther. Feb"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib243","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest. Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib244","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1471-2377-13-212","article-title":"Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis","volume":"13","author":"Durel","year":"2013","journal-title":"BMC Neurol. Dec"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib245","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40744-022-00424-1","article-title":"Anti-TNF induced sarcoidosis-like disease in rheumatoid arthritis patients: review cases from the RA UCLouvain Brussels cohort","volume":"9","author":"Theunssens","year":"2022","journal-title":"Rheumatol Ther. Apr"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib246","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases","volume":"48","author":"Da\u00efen","year":"2009","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib247","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/rheumatology\/ker166","article-title":"Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor-alpha therapy","volume":"50","author":"Salvatierra","year":"2011","journal-title":"Rheumatology"},{"issue":"5 Suppl1","key":"10.1016\/j.jaut.2024.103179_bib248","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin Arthritis Rheum. Apr"},{"key":"10.1016\/j.jaut.2024.103179_bib249","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1066454","article-title":"Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment","volume":"14","author":"Offman","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103179_bib250","unstructured":"border-box Cgc-g-rn-c-cn-c-csb-s, 20px f-s, color: rgb(27, 27), et al. A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis (NCT05890729). Accessed July 20, 2023, https:\/\/www.clinicaltrials.gov\/study\/NCT05890729?cond=sarcoidosis&term=Xentria&rank=1."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib251","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/09273941003797934","article-title":"The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas","volume":"18","author":"Rosenbaum","year":"2010","journal-title":"Ocul Immunol Inflamm. Aug"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib252","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib253","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000236532","article-title":"Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis","volume":"102","author":"Terao","year":"1993","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib254","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1164\/rccm.201005-0792OC","article-title":"Dysregulation of p38 and MKP-1 in response to NOD1\/TLR4 stimulation in sarcoid bronchoalveolar cells","volume":"183","author":"Rastogi","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2024.103179_bib256","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib257","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature","volume":"93","author":"Wang","year":"2020","journal-title":"Yale J Biol Med. 03"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib258","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clim.2009.04.010","article-title":"Hypothesis: sarcoidosis is a STAT1-mediated disease","volume":"132","author":"Rosenbaum","year":"2009","journal-title":"Clin Immunol. Aug"},{"key":"10.1016\/j.jaut.2024.103179_bib259","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","author":"Damsky","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib260","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2005.25.733","article-title":"Stats: multifaceted regulators of transcription","volume":"25","author":"Brierley","year":"2005","journal-title":"J Interferon Cytokine Res. Dec"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib261","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J Leukoc Biol. Sep"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib262","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jaad.2019.06.1297","article-title":"Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders","volume":"82","author":"Rosenbach","year":"2020","journal-title":"J Am Acad Dermatol. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib263","first-page":"98","article-title":"Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis","volume":"596","author":"Li","year":"2017","journal-title":"Gene. Jan 5"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib264","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.yexmp.2014.04.006","article-title":"Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis","volume":"96","author":"Christophi","year":"2014","journal-title":"Exp. Mol. Pathol."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib265","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103179_bib266","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib267","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis. Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib268","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med. Jan 27"},{"key":"10.1016\/j.jaut.2024.103179_bib269","unstructured":"FDA Safety Alert. Medwatch. Xeljanz, Xeljanz XR (tofacitinib): Drug safety communication - due to an increased risk of blood clots and death with higher dose. Accessed August 28, 2023. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib270","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol. Oct"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib271","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis. Jun"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib272","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol. Jun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib273","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study","volume":"61","author":"Desai","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib274","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib275","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41584-022-00832-1","article-title":"Sarcoidosis: can tofacitinib slay the dragon?","volume":"18","author":"Sweiss","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib276","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1843.1998.tb00130.x","article-title":"Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis","volume":"3","author":"Itoh","year":"1998","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib277","first-page":"139","article-title":"Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis","volume":"13","author":"Ishioka","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Sep"},{"issue":"7\u20138","key":"10.1016\/j.jaut.2024.103179_bib278","first-page":"336","article-title":"[Cytokines TNF-alpha and GM-CSF in BAL from two different segments of lungs defined by high resolution computerized tomography (HRCT) in patients with sarcoidosis]","volume":"68","author":"Ziora","year":"2000","journal-title":"Pneumonol. Alergol. Pol."},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib279","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/thx.48.12.1230","article-title":"Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis","volume":"48","author":"Itoh","year":"1993","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-017-1267-3","article-title":"Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis","volume":"19","author":"Huizinga","year":"2017","journal-title":"Arthritis Res Ther. Mar 9"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib281","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CP203235","article-title":"Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men","volume":"56","author":"Tanaka","year":"2018","journal-title":"Int J Clin Pharmacol Ther. Nov"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib282","first-page":"318","article-title":"Namilumab improves RA symptoms","volume":"15","author":"Onuora","year":"2019","journal-title":"Nat Rev Rheumatol. Jun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib283","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib284","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br J Dermatol. Jun"},{"key":"10.1016\/j.jaut.2024.103179_bib285","author":"Gov"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib286","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13023-020-01546-x","article-title":"Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis","volume":"15","author":"Katayama","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib287","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1620\/tjem.243.77","article-title":"Elevated serum anti-GM-CSF antibodies before the onset of autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis and systemic sclerosis","volume":"243","author":"Yamasue","year":"2017","journal-title":"Tohoku J Exp Med. 09"},{"key":"10.1016\/j.jaut.2024.103179_bib288","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752856","article-title":"The role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review","volume":"12","author":"Ataya","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib289","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coi.2009.09.004","article-title":"Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages","volume":"21","author":"Trapnell","year":"2009","journal-title":"Curr Opin Immunol. Oct"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib290","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis","volume":"356","author":"Uchida","year":"2007","journal-title":"N Engl J Med. Feb 8"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib291","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3892\/ol.2014.2608","article-title":"mTOR pathway: A current, up-to-date mini-review (Review)","volume":"8","author":"Zarogoulidis","year":"2014","journal-title":"Oncol Lett. Dec"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib292","first-page":"274","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell. Apr 13"},{"key":"10.1016\/j.jaut.2024.103179_bib293","article-title":"High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis","volume":"177","author":"Pizzini","year":"2021","journal-title":"Respir Med. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib294","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00430-2019","article-title":"Exome sequencing and pathogenicity-network analysis of 5 French families implicate mTOR signalling and autophagy in familial sarcoidosis","author":"Calender","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaut.2024.103179_bib295","article-title":"Sarcoidosis incidence after mTOR inhibitor treatment","volume":"57","author":"Baker","year":"2022","journal-title":"Semin Arthritis Rheum. Dec"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib296","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib297","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab. Mar 4"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib298","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2024.103179_bib299","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202004-0914IM","article-title":"Successful response to treatment with sirolimus in pulmonary sarcoidosis","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med. Jul"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib300","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/j.1432-2277.2011.01256.x","article-title":"Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation","volume":"24","author":"Manzia","year":"2011","journal-title":"Transpl Int. Aug"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib301","first-page":"13","article-title":"Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus","author":"Kelleher","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib302","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect. Feb 11"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib303","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.4.2.4","article-title":"One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis","volume":"4","author":"Ibrahim","year":"2015","journal-title":"Transl Vis Sci Technol. Mar"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib304","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ophtha.2020.03.033","article-title":"Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the sirolimus study assessing double-masked uveitis treatment (SAKURA) program","volume":"127","author":"Merrill","year":"2020","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib305","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masKed uveitis TReAtment (sakura)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology. Nov"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib306","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000303","article-title":"T-cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells","volume":"22","author":"Broos","year":"2016","journal-title":"Curr Opin Pulm Med. Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib307","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"6029","key":"10.1016\/j.jaut.2024.103179_bib308","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib309","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2013","journal-title":"Eur Respir J. Jan"},{"issue":"6204","key":"10.1016\/j.jaut.2024.103179_bib310","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib311","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib312","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1136\/gutjnl-2014-308541","article-title":"Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4","volume":"64","author":"Zeissig","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib313","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","article-title":"Abatacept for the treatment of rheumatoid arthritis","volume":"15","author":"Pombo-Suarez","year":"2019","journal-title":"Expert Rev Clin Immunol. Apr"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib314","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"issue":"Suppl 2","key":"10.1016\/j.jaut.2024.103179_bib315","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/ar1688","article-title":"The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7","author":"Ruderman","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib316","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1742-7843.2009.00375.x","article-title":"Abatacept, a novel CD80\/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis","volume":"104","author":"Korhonen","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol. Apr"},{"issue":"34","key":"10.1016\/j.jaut.2024.103179_bib317","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22340","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess. Jun"},{"key":"10.1016\/j.jaut.2024.103179_bib318","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","author":"Ostergaard","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib319","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","article-title":"Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study","volume":"59","author":"Gron","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib320","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib321","article-title":"Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial","volume":"19","author":"Frye","year":"2020","journal-title":"Contemp Clin Trials Commun. Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117157","article-title":"MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response","volume":"241","author":"Kirk","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.jaut.2024.103179_bib323","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/DDDT.S25426","article-title":"Kinase inhibitors: a new class of antirheumatic drugs","volume":"6","author":"Kyttaris","year":"2012","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib324","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2008.104802","article-title":"Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy","volume":"69","author":"Alten","year":"2010","journal-title":"Ann Rheum Dis. Feb"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib325","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"Cohen","year":"2009","journal-title":"Arthritis Rheum. Feb"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib326","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum. May"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib327","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3899\/jrheum.100602","article-title":"A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis","volume":"38","author":"Genovese","year":"2011","journal-title":"J Rheumatol. May"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib328","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gut.2009.179994","article-title":"A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease","volume":"59","author":"Dotan","year":"2010","journal-title":"Gut. Jun"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib329","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17476348.2023.2183193","article-title":"An expert overview of pulmonary fibrosis in sarcoidosis","volume":"17","author":"Gupta","year":"2023","journal-title":"Expert Rev Respir Med. Feb"},{"key":"10.1016\/j.jaut.2024.103179_bib330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib331","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.129.6.1584","article-title":"Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis","volume":"129","author":"Kruit","year":"2006","journal-title":"Chest. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib332","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2249.2006.03008.x","article-title":"Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis","volume":"143","author":"Pabst","year":"2006","journal-title":"Clin Exp Immunol. Mar"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib333","first-page":"112","article-title":"Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens","volume":"77","author":"Heron","year":"2011","journal-title":"Feb"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib334","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1183\/09031936.00010209","article-title":"CARD15\/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis","volume":"35","author":"Sato","year":"2010","journal-title":"Eur Respir J. Feb"},{"key":"10.1016\/j.jaut.2024.103179_bib335","article-title":"Inclusivity in research matters: variants in PVT1 specific to people of african descent are associated with pulmonary fibrosis","author":"Garman","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib336","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PAS.0b013e3182785a2d","article-title":"End-stage sarcoid lung disease is distinct from usual interstitial pneumonia","volume":"37","author":"Xu","year":"2013","journal-title":"Am J Surg Pathol. Apr"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib337","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir Med. Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib338","first-page":"11","article-title":"Comparative analysis of gene expression in fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis","author":"Kamp","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib339","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e3283486d52","article-title":"Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum","volume":"17","author":"Shigemitsu","year":"2011","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib340","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.15-0615","article-title":"Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest. Feb"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib341","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1202891","article-title":"Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis","volume":"190","author":"Oswald-Richter","year":"2013","journal-title":"J Immunol. Jun"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib342","article-title":"The circulating Treg\/Th17 cell ratio is correlated with relapse and treatment response in pulmonary sarcoidosis patients after corticosteroid withdrawal","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2024.103179_bib343","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106371","article-title":"Antifibrotic drugs for pulmonary sarcoidosis: a treatment in search of an indication","volume":"180","author":"Judson","year":"2021","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib344","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","article-title":"Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"17","author":"Canavan","year":"2016","journal-title":"Am J Clin Dermatol. Feb"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib346","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol. Mar"},{"issue":"10091","key":"10.1016\/j.jaut.2024.103179_bib347","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib348","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol Ther (Heidelb). Dec"},{"issue":"10273","key":"10.1016\/j.jaut.2024.103179_bib349","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet. Feb"},{"issue":"16","key":"10.1016\/j.jaut.2024.103179_bib350","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib351","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, Ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib352","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatol Venereol. Jun"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib353","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ced.14101","article-title":"Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis","volume":"45","author":"Eichhoff","year":"2020","journal-title":"Clin Exp Dermatol. Jun"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib354","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib355","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/09273948.2019.1569245","article-title":"Poor control of sarcoidosis-related panuveitis with an antibody to IL-23","volume":"28","author":"Thomas","year":"2020","journal-title":"Ocul Immunol Inflamm. 04"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib356","first-page":"E494","article-title":"Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis","volume":"48","author":"Lu","year":"2021","journal-title":"J Dermatol. Oct"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib357","first-page":"14","article-title":"Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis","author":"Kirby","year":"2021","journal-title":"BMJ Case Rep. Feb 22"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib358","first-page":"e187","article-title":"Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis","volume":"63","author":"Hlaca","year":"2022","journal-title":"Australas J Dermatol. May"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib359","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.chest.2021.04.032","article-title":"Inhibiting OX40 restores regulatory T-cell function and suppresses inflammation in pulmonary sarcoidosis","volume":"160","author":"Kumari","year":"2021","journal-title":"Chest. Sep"},{"issue":"3\u20134","key":"10.1016\/j.jaut.2024.103179_bib360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","article-title":"Immune regulation and control of regulatory T cells by OX40 and 4-1BB","volume":"19","author":"So","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jaut.2024.103179_bib361","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","article-title":"A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity","volume":"95","author":"Kumar","year":"2018","journal-title":"J Autoimmun. Dec"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib362","article-title":"New pathways in immune stimulation: targeting OX40. ESMO Open","volume":"5","author":"Alves Costa Silva","year":"2020","journal-title":"Feb"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib363","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3892\/etm.2023.11923","article-title":"Inhibition of phosphoinositide-3 kinases gamma\/delta ameliorates pulmonary granuloma by rescuing Treg function in a sarcoidosis model","volume":"25","author":"Zhang","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib364","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/jpet.110.169961","article-title":"Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro","volume":"335","author":"Wang","year":"2010","journal-title":"J Pharmacol Exp Ther. Dec"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib365","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.12-0383","article-title":"Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis","volume":"143","author":"Julian","year":"2013","journal-title":"Chest. Feb"},{"key":"10.1016\/j.jaut.2024.103179_bib366","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Goncalves","year":"2021","journal-title":"Drugs Context"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib367","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib368","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med. Feb"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib369","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"26","key":"10.1016\/j.jaut.2024.103179_bib370","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med. Jun 27"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib371","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med. Jan"},{"issue":"18","key":"10.1016\/j.jaut.2024.103179_bib372","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med. 10"},{"key":"10.1016\/j.jaut.2024.103179_bib373","article-title":"Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib374","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib375","article-title":"Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib376","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.rmed.2013.10.014","article-title":"Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients","volume":"107","author":"Baughman","year":"2013","journal-title":"Respir Med. Dec"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib377","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am J Med Sci. Jan"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib378","article-title":"Efzofitimod: a novel anti-inflammatory agent for sarcoidosis","volume":"40","author":"Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Mar 28"},{"key":"10.1016\/j.jaut.2024.103179_bib379","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3389\/fimmu.2017.01228","article-title":"Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy","volume":"8","author":"Roy","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103179_bib380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","article-title":"Role of neuropilin-2 in the immune system","volume":"90","author":"Schellenburg","year":"2017","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib381","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1002\/iid3.575","article-title":"Neuropilin-2 regulates airway inflammation in a neutrophilic asthma model","volume":"10","author":"Immormino","year":"2022","journal-title":"Immun Inflamm Dis. Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib382","article-title":"Novel protein pathways in development and progression of pulmonary sarcoidosis","volume":"10","author":"Bhargava","year":"2020","journal-title":"Sci Rep. Aug"},{"issue":"Suppl 65","key":"10.1016\/j.jaut.2024.103179_bib383","first-page":"OA3986","article-title":"Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation","volume":"58","author":"Paz","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib384","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest. Apr"},{"key":"10.1016\/j.jaut.2024.103179_bib385","unstructured":"ClinicalTrialsGov. Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis. U.S. National Library of Medicine. Accessed June 25, 2022, https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05415137."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib386","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1513\/AnnalsATS.202006-607OC","article-title":"Evaluating the minimal clinically important difference of the king's sarcoidosis Questionnaire in a multicenter prospective study","volume":"18","author":"Baughman","year":"2021","journal-title":"Ann Am Thorac Soc. Mar"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib387","first-page":"623","article-title":"Histidyl-tRNA synthetase","volume":"380","author":"Freist","year":"1999","journal-title":"Biol Chem. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib388","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaut.2004.01.004","article-title":"Intracellular localization of histidyl-tRNA synthetase\/Jo-1 antigen in T24 cells and some other cells","volume":"22","author":"Kamei","year":"2004","journal-title":"J. Autoimmun."},{"issue":"18","key":"10.1016\/j.jaut.2024.103179_bib389","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1021\/bi00392a044","article-title":"Purification of mammalian histidyl-tRNA synthetase and its interaction with myositis-specific anti-Jo-1 antibodies","volume":"26","author":"Fahoum","year":"1987","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.jaut.2024.103179_bib390","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jaut.2024.103179_bib391","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.rmed.2016.10.003","article-title":"Smoking, obesity and risk of sarcoidosis: a population-based nested case-control study","volume":"120","author":"Ungprasert","year":"2016","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib392","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/thx.43.7.516","article-title":"Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease","volume":"43","author":"Valeyre","year":"1988","journal-title":"Thorax. Jul"},{"key":"10.1016\/j.jaut.2024.103179_bib393","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1749-6632.1986.tb18539.x","article-title":"Reduced prevalence of smokers in sarcoidosis. Results of a case-control study","volume":"465","author":"Harf","year":"1986","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib394","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/rccm.200909-1338OC","article-title":"Smoking, use of moist snuff, and risk of chronic inflammatory diseases","volume":"181","author":"Carlens","year":"2010","journal-title":"Am J Respir Crit Care Med. Jun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib395","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54612-1","article-title":"A gene-environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis","volume":"9","author":"Rivera","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib396","first-page":"138","article-title":"Cigarette smoking and male sex are independent and age concomitant risk factors for the development of ocular sarcoidosis in a New Orleans sarcoidosis population","volume":"32","author":"Janot","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Jul"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib397","first-page":"19","article-title":"Is tobacco smoking protective for sarcoidosis? A case-control study from North India","volume":"27","author":"Gupta","year":"2010","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. : official journal of WASOG"},{"issue":"9\u201310","key":"10.1016\/j.jaut.2024.103179_bib398","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2119\/2008-00079.Parrish","article-title":"Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling","volume":"14","author":"Parrish","year":"2008","journal-title":"Mol Med"},{"issue":"6921","key":"10.1016\/j.jaut.2024.103179_bib399","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature01339","article-title":"Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation","volume":"421","author":"Wang","year":"2003","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib400","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.4049\/jimmunol.0902212","article-title":"Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses","volume":"183","author":"Nizri","year":"2009","journal-title":"J Immunol. Nov 15"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib401","first-page":"189","article-title":"Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology","volume":"23","author":"Sopori","year":"1998","journal-title":"Feb"},{"key":"10.1016\/j.jaut.2024.103179_bib402","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.053","article-title":"Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB","volume":"1256","author":"Marrero","year":"2009","journal-title":"Brain Res. Feb"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib403","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/taap.1995.1233","article-title":"Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes","volume":"135","author":"Geng","year":"1995","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib404","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2249.2006.03169.x","article-title":"Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7","volume":"146","author":"Yoshikawa","year":"2006","journal-title":"Clin Exp Immunol. Oct"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib405","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-010-1549-4","article-title":"Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"32","author":"Zhou","year":"2012","journal-title":"Rheumatol Int. Jan"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib406","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s10753-019-01027-9","article-title":"Alpha7 nicotinic acetylcholine receptor alleviates inflammatory bowel disease through induction of AMPK-mTOR-p70S6K-mediated autophagy","volume":"42","author":"Shao","year":"2019","journal-title":"Inflammation. Oct"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib407","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chest.2021.05.031","article-title":"A pilot randomized trial of transdermal nicotine for pulmonary sarcoidosis","volume":"160","author":"Crouser","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaut.2024.103179_bib408","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100669","article-title":"Design, rationale, and baseline characteristics of a pilot randomized clinical trial of nicotine treatment for pulmonary sarcoidosis","volume":"20","author":"Hade","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib409","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1172\/JCI110036","article-title":"Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes","volume":"67","author":"Hunninghake","year":"1981","journal-title":"J Clin Invest. Jan"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib410","first-page":"535","article-title":"Systemic immune response of patients with active pulmonary sarcoidosis","volume":"61","author":"Baughman","year":"1985","journal-title":"Clin Exp Immunol. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib411","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0049-0172(00)80019-0","article-title":"Anti-dsDNA antibodies in sarcoidosis","volume":"29","author":"Weinberg","year":"2000","journal-title":"Semin Arthritis Rheum. Apr"},{"key":"10.1016\/j.jaut.2024.103179_bib412","article-title":"The prevalence of antinuclear antibodies in patients with sarcoidosis","volume":"2014","author":"Kobak","year":"2014","journal-title":"Autoimmune Dis."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib413","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1378\/chest.74.3.261","article-title":"Immune complexes in sarcoidosis: a correlation with activity and duration of disease","volume":"74","author":"Daniele","year":"1978","journal-title":"Chest. Sep"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2024.103179_bib414","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000195495","article-title":"Study of immune complexes in bronchoalveolar lavage fluids","volume":"54","author":"Dall'Aglio","year":"1988","journal-title":"Respiration"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib415","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/thx.47.11.964","article-title":"B lymphocyte accumulations in human pulmonary sarcoidosis","volume":"47","author":"Fazel","year":"1992","journal-title":"Thorax. Nov"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib416","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043588","article-title":"Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels","volume":"7","author":"Saussine","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib417","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/CVI.05118-11","article-title":"Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis","volume":"18","author":"Lee","year":"2011","journal-title":"Clin Vaccine Immunol. Aug"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib418","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.2001.5197","article-title":"Absence of memory B cells in patients with common variable immunodeficiency","volume":"103","author":"Agematsu","year":"2002","journal-title":"Clin Immunol. Apr"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib419","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1164\/ajrccm.163.1.9906071","article-title":"Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis","volume":"163","author":"Wahlstrom","year":"2001","journal-title":"Am J Respir Crit Care Med. Jan"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib420","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib422","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","article-title":"Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry","volume":"64","author":"Puechal","year":"2012","journal-title":"Arthritis Care Res (Hoboken). Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib423","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ced.12793","article-title":"Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis?","volume":"41","author":"Galimberti","year":"2016","journal-title":"Clin Exp Dermatol. Jun"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib424","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J. May"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib425","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir","year":"2022","journal-title":"J Card Fail. Feb"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib426","article-title":"Neurosarcoidosis: longitudinal experience in a single-center, academic healthcare system","volume":"7","author":"Lord","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm. Jul"},{"key":"10.1016\/j.jaut.2024.103179_bib427","first-page":"1613","article-title":"Rituximab for refractory granulomatous eye disease","volume":"6","author":"Lower","year":"2012","journal-title":"Clin. Ophthalmol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib428","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jbspin.2008.01.025","article-title":"Rituximab as a treatment alternative in sarcoidosis","volume":"75","author":"Belkhou","year":"2008","journal-title":"Joint Bone Spine. Jul"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib429","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: a single centre experience","volume":"13","author":"Cinetto","year":"2015","journal-title":"Clin. Mol. Allergy"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib430","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jbspin.2009.11.005","article-title":"Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case","volume":"77","author":"Dasilva","year":"2010","journal-title":"Joint Bone Spine. Jan"},{"issue":"10","key":"10.1016\/j.jaut.2024.103179_bib431","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol. Oct"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib432","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1684\/ejd.2017.3143","article-title":"Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?","volume":"27","author":"Pescitelli","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jaut.2024.103179_bib433","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13693","article-title":"Scar sarcoidosis following rituximab therapy","author":"Vesely","year":"2020","journal-title":"Dermatol Ther. May"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib434","first-page":"1116","article-title":"Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr Opin Investig Drugs","volume":"6","author":"Gonzalez-Rey","year":"2005","journal-title":"Nov"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib435","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00109-001-0291-5","article-title":"Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases","volume":"80","author":"Delgado","year":"2002","journal-title":"J Mol Med (Berl). Jan"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib436","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nri1984","article-title":"Regulation of immune tolerance by anti-inflammatory neuropeptides","volume":"7","author":"Gonzalez-Rey","year":"2007","journal-title":"Nat Rev Immunol. Jan"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib437","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1189\/jlb.0605299","article-title":"Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo","volume":"78","author":"Delgado","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib438","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.21652","article-title":"Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis","volume":"54","author":"Gonzalez-Rey","year":"2006","journal-title":"Arthritis Rheum. Mar"},{"issue":"11","key":"10.1016\/j.jaut.2024.103179_bib439","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2174\/138161207780618966","article-title":"Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator","volume":"13","author":"Gonzalez-Rey","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaut.2024.103179_bib440","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6043710","article-title":"The anti-inflammatory mediator, vasoactive intestinal peptide, modulates the differentiation and function of Th subsets in rheumatoid arthritis","volume":"2018","author":"Villanueva-Romero","year":"2018","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib441","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.200909-1451OC","article-title":"Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis","volume":"182","author":"Prasse","year":"2010","journal-title":"Am J Respir Crit Care Med. Aug"},{"issue":"9","key":"10.1016\/j.jaut.2024.103179_bib442","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal. Sep"},{"key":"10.1016\/j.jaut.2024.103179_bib443","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib444","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","article-title":"A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib445","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol. Feb"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib446","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis. Oct"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib447","first-page":"121","article-title":"Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"Park","year":"2009","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. : official journal of WASOG. Jul"},{"issue":"7","key":"10.1016\/j.jaut.2024.103179_bib448","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","article-title":"Apremilast: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs. May"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib450","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol. Feb"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib451","article-title":"Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","author":"Baughman","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"1S","key":"10.1016\/j.jaut.2024.103179_bib452","first-page":"S19","article-title":"NAEPP guidelines update and GINA 2021-asthma care differences, overlap, and challenges","volume":"10","author":"Chipps","year":"2020","journal-title":"J Allergy Clin Immunol Pract. Jan"},{"key":"10.1016\/j.jaut.2024.103179_bib453","article-title":"Cardiac sarcoidosis: systematic review of literature on corticosteroid and immunosuppressive therapies","author":"Stievenart","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2024.103179_bib454","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol. Feb 1"},{"key":"10.1016\/j.jaut.2024.103179_bib455","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J. 02"},{"issue":"155","key":"10.1016\/j.jaut.2024.103179_bib456","article-title":"The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review","volume":"29","author":"Vis","year":"2020","journal-title":"Eur Respir Rev. Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib457","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.jaut.2024.103179_bib458","unstructured":"ClinicalTrialsGov. Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (PREDMETH). U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314193."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib459","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum. 10"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib460","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12890-021-01761-7","article-title":"FeV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients","volume":"21","author":"Frye","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib461","article-title":"Identifying a core outcome set for pulmonary sarcoidosis research - the foundation for sarcoidosis research - sarcoidosis clinical OUtcomes taskforce (SCOUT)","volume":"39","author":"Harman","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis. : official journal of WASOG"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib462","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/MCP.0000000000000704","article-title":"Socioeconomic determinants and disparities in sarcoidosis","volume":"26","author":"Sharp","year":"2020","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib463","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1164\/rccm.201906-1250OC","article-title":"Income and other contributors to poor outcomes in U.S. Patients with sarcoidosis","volume":"201","author":"Harper","year":"2020","journal-title":"Am J Respir Crit Care Med. 04"},{"issue":"Supplement_6","key":"10.1016\/j.jaut.2024.103179_bib464","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1513\/AnnalsATS.201707-564OT","article-title":"Disease burden and variability in sarcoidosis","volume":"14","author":"Gerke","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.jaut.2024.103179_bib465","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib466","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1183\/09031936.01.00056201","article-title":"Sarcoidosis severity and socioeconomic status","volume":"18","author":"Rabin","year":"2001","journal-title":"Eur Respir J. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib467","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest. May"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib468","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s13063-022-06144-9","article-title":"Success and failure factors of patient recruitment for industry-sponsored clinical trials and the role of the electronic health records-a qualitative interview study in the Nordic countries","volume":"23","author":"Laaksonen","year":"2022","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib469","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr. Probl. Cardiol."},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib470","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pec.2014.10.018","article-title":"Outcomes from the Body & Soul Clinical Trials Project: a university-church partnership to improve African American enrollment in a clinical trial registry","volume":"98","author":"Langford","year":"2015","journal-title":"Patient Educ Couns. Feb"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2024.103179_bib471","first-page":"i47","article-title":"Conducting research in psoriatic arthritis: the emerging role of patient research partners. Rheumatology (Oxford)","volume":"59","author":"Goel","year":"2020","journal-title":"Mar"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib472","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1369-7625.2011.00661.x","article-title":"Collaboration and co-ownership in research: dynamics and dialogues between patient research partners and professional researchers in a research team","volume":"15","author":"Nierse","year":"2012","journal-title":"Health Expect. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib473","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002241","article-title":"Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences","volume":"3","author":"de Wit","year":"2013","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib474","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00441-016-2526-3","article-title":"Animal models of sarcoidosis","volume":"367","author":"Hu","year":"2017","journal-title":"Cell Tissue Res. Mar"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib475","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MCP.0000000000000708","article-title":"Experimental models of sarcoidosis: where are we now?","volume":"26","author":"Jeny","year":"2020","journal-title":"Curr Opin Pulm Med. Sep"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib476","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1165\/rcmb.2016-0321OC","article-title":"A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection","volume":"57","author":"Crouser","year":"2017","journal-title":"Am J Respir Cell Mol Biol. 10"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib477","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1165\/rcmb.2018-0346OC","article-title":"Peroxisome proliferator-activated receptor-gamma deficiency exacerbates fibrotic response to mycobacteria peptide in murine sarcoidosis model","volume":"61","author":"Malur","year":"2019","journal-title":"Am J Respir Cell Mol Biol. Aug"},{"key":"10.1016\/j.jaut.2024.103179_bib478","article-title":"Transcriptional survey of alveolar macrophages in a murine model of chronic granulomatous inflammation reveals common themes with human sarcoidosis","author":"Mohan","year":"2017","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib479","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","article-title":"Predicting mortality in patients with sarcoidosis awaiting lung transplantation","volume":"124","author":"Shorr","year":"2003","journal-title":"Chest. Sep"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib480","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.05.00083404","article-title":"Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics","volume":"25","author":"Shorr","year":"2005","journal-title":"Eur Respir J. May"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib481","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/s41598-019-40030-w","article-title":"Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension","volume":"9","author":"Parikh","year":"2019","journal-title":"Sci Rep. Mar"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib482","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J. Jan"},{"issue":"163","key":"10.1016\/j.jaut.2024.103179_bib483","first-page":"31","article-title":"WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur Respir Rev. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib484","first-page":"PA3274","article-title":"Functional and symptomatic burden of small fiber neuropathy in sarcoidosis","volume":"50","author":"Culver","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jaut.2024.103179_bib485","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000000597","article-title":"Nonorgan manifestations of sarcoidosis","author":"Tavee","year":"2019","journal-title":"Curr Opin Pulm Med. Jun"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib486","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"Tavee","year":"2011","journal-title":"Curr Pain Headache Rep. Jun"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib487","first-page":"127","article-title":"The relationship between fatigue and clinical parameters in pulmonary sarcoidosis","volume":"21","author":"De Vries","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis. Jun"},{"issue":"5","key":"10.1016\/j.jaut.2024.103179_bib488","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"Lower","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib489","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial","volume":"45","author":"Lower","year":"2013","journal-title":"J Pain Symptom Manage. Feb"},{"issue":"3","key":"10.1016\/j.jaut.2024.103179_bib490","first-page":"235","article-title":"The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis","volume":"22","author":"Wagner","year":"2005","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib491","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-007-0996-4","article-title":"Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis","volume":"197","author":"Peterson","year":"2008","journal-title":"Psychopharmacology (Berl). Mar"},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib492","article-title":"Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis","volume":"39","author":"Raasing","year":"2022","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"4","key":"10.1016\/j.jaut.2024.103179_bib493","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2014.892072","article-title":"ARA 290 for treatment of small fiber neuropathy in sarcoidosis","volume":"23","author":"van Velzen","year":"2014","journal-title":"Expert Opin Investig Drugs. Apr"},{"issue":"6","key":"10.1016\/j.jaut.2024.103179_bib494","doi-asserted-by":"crossref","first-page":"BIO52","DOI":"10.1167\/iovs.16-21291","article-title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","volume":"58","author":"Culver","year":"2017","journal-title":"Invest Ophthalmol Vis Sci. 05"},{"key":"10.1016\/j.jaut.2024.103179_bib495","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2119\/molmed.2012.00332","article-title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","volume":"18","author":"Heij","year":"2012","journal-title":"Mol Med. Nov"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib496","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/PR9.0000000000000566","article-title":"Targeting the innate repair receptor to treat neuropathy","volume":"1","author":"Dahan","year":"2016","journal-title":"Pain Rep. Jul"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib497","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2119\/molmed.2014.00215","article-title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","volume":"20","author":"Brines","year":"2015","journal-title":"Mol Med. Mar 13"},{"issue":"1","key":"10.1016\/j.jaut.2024.103179_bib498","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","article-title":"Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis","volume":"952","author":"Agnello","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.jaut.2024.103179_bib499","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol Med. Nov"},{"issue":"2","key":"10.1016\/j.jaut.2024.103179_bib500","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol. Mar"},{"key":"10.1016\/j.jaut.2024.103179_bib501","unstructured":"ClinicalTrialsGov. A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis (RESOLVE-Heart). U.S. National Library of Medicine. Accessed June 27, 2022, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05351554."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T11:41:13Z","timestamp":1738496473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":497,"alternative-id":["S0896841124000131"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103179","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developmental drugs for sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103179"}}